Latest News

Oslo, Norway, 10 June 2020: Photocure ASA (OSE:PHO) today announces the company’s first sustainability report, which will be presented at the Annual General Meeting (AGM) at 17:00 CET. The AGM will be live streamed and Dan Schneider, President & Chief Executive Officer, will provide a general company update.

Oslo, Norway, 8 June 2020: Reference is made to the stock exchange announcement by Photocure ASA ("Photocure") published 2 May 2019 regarding a share capital increase as part of the employee long-term incentive program for restricted shares in the company.

Oslo, Norway, June 5, 2020 - Photocure ASA (OSE: PHO) will be presenting at the annual ABG Sundal Collier Virtual Oncology Seminar on June 10. This event features Norwegian companies in the oncology space.

Oslo, Norway, 27 May 2020: Reference is made to the stock exchange announcement by Photocure ASA ("Photocure") published 25 May 2020 regarding a share capital increase following the exercise of employee share options.

Oslo, Norway, 25 May 2020.

Participants in the Photocure ASA’s share option program have on 25 May 2020 exercised a total of 123,750 options. The share options are exercised at an average strike price of NOK 40.81. Each option gives a right to receive one share in the company. The share options are described in note 7 in Photocure’s annual financial statements of 2019.

Oslo, Norway, 20 May 2020: Photocure ASA (OSE: PHO), calls for the annual general meeting (webcast) of PHO to be held at Advokatfirmaet Selmer AS' premises in Tjuvholmen allé 1, 0252 Oslo, Norway on 10 June 2020 at 17:00 hours (CET).

OSLO, Norway, 15 May 2020 -- Photocure ASA (OSE: PHO) today announced key data was published by the 2020 American Urological Association (AUA) Annual Virtual Meeting. Three abstracts featured Blue Light Cystoscopy (BLC™) with Cysview, and on June 27, 2020 BLC with Cysview will be included in a virtual session of the AUA program: “Surgical Techniques: Tips & Tricks Oncology: Bladder Cancer Blue Light” with Dr. Anne Schuckman.

Oslo, Norway, 7 May 2020: Photocure ASA (OSE:PHO) announced the first quarter 2020 results in the trading update 27 April 2020, stating a revenue growth of 33% for the U.S. market in the first quarter of 2020, contributing to Hexvix^®/Cysview^® revenues of NOK 54.4 million (Q1 2019: NOK 51.2 million) and an EBITDA of NOK -4.8 million (NOK -1.5 million). The company has agreed terms with Ipsen Pharma SAS (Ipsen) for the return of Hexvix sales, marketing and distribution rights from the fourth quarter of 2020 and sees significant growth opportunities in Europe. The agreement is expected to be EBITDA accretive from full-year 2021 and beyond.

Oslo, Norway, 30 April 2020: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2020 financial results on Thursday 7 May 2020 at 07:00 CET and invites investors, analysts and the media to a presentation at 15:00 CET the same day.

Oslo, Norway, 28 April 2020: Board member Einar Antonsen has notified Photocure ASA that he resigns as a member of the board of directors of Photocure with immediate effect.

Oslo, Norway, 28 April 2020: Reference is made to the previous stock exchange notices where Photocure ASA ("Photocure" or the "Company") announced the allocation of 2,179,638 shares at a subscription price of NOK 65.50 per share, raising gross proceeds of approximately NOK 143 million in a private placement (the "Private Placement") .

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

HIGHLIGHTS

• Photocure has reached an agreement with Ipsen to regain rights for the sales and marketing of Hexvix^® in Europe
• The transaction is expected to be EBITDA accretive from FY 2021
• Ipsen achieved Hexvix 2019 sales of EUR 18.7 million and Photocure sees significant growth opportunities in Europe

With reference to the senior management share option program in Photocure ASA ("Photocure" or "Company"), on 7 April 2020 the Board of Directors in Photocure resolved the issue of in total 500,000 share options for 2019.

Oslo, 8 April 2020: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2019.

Oslo, Norway, 7 April 2020: The Board of Directors and Management of Photocure ASA (OSE:PHO) follow the COVID-19 situation closely and have implemented strict measures to ensure the safety of patients, customers, employees and business partners while maintaining an uninterrupted level of service and supply. The company today provides the second COVID-19 Oslo Stock Exchange notification to ensure updated and transparent stakeholder information.

Oslo, Norway, 19 March 2020: The management of Photocure ASA (OSE:PHO) is following the Covid-19 situation closely and has implemented strict measures to ensure the safety of patients, customers, employees and business partners while maintaining an uninterrupted level of service and supply.

Oslo, Norway, 27 February 2020: Photocure ASA (OSE:PHO), today reported a revenue growth of 51% for the U.S. market in the fourth quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 58.8 million (Q4 2018: NOK 46.3) and a recurring EBITDA of NOK 1.6 million (NOK 1.3 million).